Apoptosis induced by 7-difluoromethoxyl-5,4′-di-n-octyl genistein via the inactivation of FoxM1 in ovarian cancer cells

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 1857-1864

  Ning, Yingxia ^a   Li, Qingxiu ^a   Xiang, Honglin ^b   Liu, Fei ^b   Cao, Jianguo ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

Author keywords

7 difluoromethoxyl 5,4 di n octylgenistein; Apoptosis; Forkhead box protein M1; Genistein; Ovarian cancer

Indexed keywords

7 DIFLUOROMETHOXYL 5,4' DI N OCTYL GENISTEIN; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CARCINOGENESIS; CDC25B GENE; CELL CYCLE ARREST; CONTROLLED STUDY; CYCLIN B GENE; DNA TRANSFECTION; DOWN REGULATION; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOXM1 GENE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; OVARY CANCER; P27KIP1 GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVIN GENE; TUMOR GENE; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CDC25 PHOSPHATASES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; G2 PHASE CELL CYCLE CHECKPOINTS; GENISTEIN; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; OVARIAN NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84860777867     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1739     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Mor G, Fu HH and Alvero AB: Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr Opin Investig Drugs 7: 542-548, 2006. (Pubitemid 43891033)
3. Psyrri A, Kassar M, Yu Z, et al: Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 11: 8637-8643, 2005. (Pubitemid 43005911)
4. Ozols RF: Treatment goals in ovarian cancer. Int J Gynecol Cancer 15 (Suppl) 1: 3-11, 2005.
5. Cunha-Rodrigues M, Portugal S, Prudencio M, et al: Genistein-supplemented diet decreases malaria liver infection in mice and constitutes a potential prophylactic strategy. PLoS One 3: e2732, 2008.
6. Zhou HB, Chen JM, Cai JT, Du Q and Wu CN: Anticancer activity of genistein on implanted tumor of human SG7901 cells in nude mice. World J Gastroenterol 14: 627-631, 2008. (Pubitemid 351320833)
7. Koo H, Schobel B, Scott-Anne K, et al: Apigenin and tt-farnesol with fluoride effects on S. mutans biofilms and dental caries. J Dent Res 84: 1016-1020, 2005. (Pubitemid 43828148)
8. Fu XH, Wang L, Zhao H, Xiang HL and Cao JG: Synthesis of genistein derivatives and determination of their protective effects against vascular endothelial cell damages caused by hydrogen peroxide. Bioorg Med Chem Lett 18: 513-517, 2008.
9. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
10. Wierstra I and Alves J: FOXM1, a typical proliferation-associated transcription factor. Biol Chem 388: 1257-1274, 2007.
11. Costa RH: FoxM1 dances with mitosis. Nat Cell Biol 7: 108-110, 2005.
12. Petrovic V, Costa RH, Lau LF, Raychaudhuri P and Tyner AL: FoxM1 regulates growth factor-induced expression of kinase-interacting stathmin (KIS) to promote cell cycle progression. J Biol Chem 283: 453-460, 2008.
13. Wang IC, Chen YJ, Hughes DE, et al: FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J Biol Chem 283: 20770-20778, 2008.
14. Chen YJ, Dominguez-Brauer C, Wang Z, et al: A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J Biol Chem 284: 30695-30707, 2009.
15. Park HJ, Carr JR, Wang Z, et al: FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J 28: 2908-2918, 2009.
16. Wang Z, Ahmad A, Banerjee S, et al: FoxM1 is a novel target of a natural agent in pancreatic cancer. Pharm Res 27: 1159-1168, 2010.
17. Ai XH, Zheng X, Tang XQ, et al: Induction of apoptosis of human gastric carcinoma SGC-7901 cell line by 5, 7-dihydroxy-8-nitrochrysin in vitro. World J Gastroenterol 13: 3824-3828, 2007. (Pubitemid 47272307)
18. Yang XH, Zheng X, Cao JG, Xiang HL, Liu F and Lv Y: 8-Bromo-7- methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK. World J Gastroenterol 16: 3385-3393, 2010.
19. Wang Z, Banerjee S, Kong D, Li Y and Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 67: 8293-8300, 2007. (Pubitemid 47395167)
20. Francis RE, Myatt SS, Krol J, et al: FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol 35: 57-68, 2009.
21. Gemenetzidis E, Bose A, Riaz AM, et al: FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One 4: e4849, 2009.
22. McGovern UB, Francis RE, Peck B, et al: Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther 8: 582-591, 2009.
23. Petrovic V, Costa RH, Lau LF, Raychaudhuri P and Tyner AL: Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. Cancer Biol Ther 9: 1008-1016, 2010.
24. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D and Lam EW: Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 7: 2022-2032, 2008.
25. Wang Z, Li Y, Ahmad A, et al: Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem 112: 78-88, 2011.
26. Barsotti AM and Prives C: Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 28: 4295-4305, 2009.
27. Ahmad A, Wang Z, Kong D, et al: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat 122: 337-346, 2010.
28. Aprelikova O, Xiong Y and Liu ET: Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 270: 18195-18197, 1995.
29. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059-1065, 1993.
30. Wang IC, Chen YJ, Hughes D, et al: Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25: 10875-10894, 2005. (Pubitemid 41747132)
31. Zhao X, Ogunwobi OO and Liu C: Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. PLoS One 6: e21980, 2011.
32. Chowdhury S, Howell GM, Teggart CA, et al: Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J Biol Chem 286: 30937-30948, 2011.
33. Rahman KW, Li Y, Wang Z, Sarkar SH and Sarkar FH: Gene expression profiling revealed survivin as a target of 3,3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 66: 4952-4960, 2006.